4D Molecular Therapeutics
FDMT
96 hedge funds and large institutions have $622M invested in 4D Molecular Therapeutics in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 25 increasing their positions, 33 reducing their positions, and 20 closing their positions.
181% more capital invested
Capital invested by funds: $221M → $622M (+$401M)
179% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $981K
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
9% more funds holding
Funds holding: 88 → 96 (+8)
1.54% more ownership
Funds ownership: 84.9% → 86.45% (+1.5%)
24% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$11.9M |
| 2 |
CC
Casdin Capital
New York
|
+$9.73M |
| 3 |
CC
Commodore Capital
New York
|
+$9.24M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.62M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$18.1M |
| 2 |
Morgan Stanley
New York
|
-$8.7M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$8.46M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.34M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.04M |
FDMT Hedge Fund Activity: Q4 2022 in Review
96 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2022, worth a combined $622M — up 181% from $221M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FDMT positions and 20 closed out — a net gain of 8 holders — while 25 added to existing stakes and 33 trimmed.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $11.9M. The largest seller was Janus Henderson Group, cutting an estimated $18.1M.
- 96 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2022, up from 88 in Q3 2022.
- Funds reported $622M of 4D Molecular Therapeutics stock for Q4 2022, up 181% quarter-over-quarter.
- 28 funds opened new 4D Molecular Therapeutics positions in Q4 2022 and 20 closed out, a net change of +8 holders.
- The largest 4D Molecular Therapeutics buyer in Q4 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $11.9M added.
- The largest 4D Molecular Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $18.1M sold.
Based on aggregated 13F filings for Q4 2022.